`IINCNoSnSTtTaRiRnUUsCCaTTsIIuOOmNNmSSarFFyOOoRRf aSSvTTaAAilFFaFFbleW WdOOaRtRaKKaSSnHHdEEoEnEgTToing staff analysis Data and Contains Data and analysisare subject to change a summary of available data and analysis are subject to change ongoing staff analysis Last Revised: 5/3/17 Last Revised: 5/3/17 PPeerrfflluuoorrooooccttaannooiicc AAcciidd Supplement to Original Review (completed on 12/07/2007) ReS-uEpvpalleumateinotntoFoOcruigseindaol nReKveiyewSt(ucdoimesplIedteendtiofnie1d2i/n07U/S20E07P)A Health Effects Support Re-Evaluation Focused on Health Effects Support Documents Released May Key Studies Identified in Documents Released May 2016 [IS EPA 2016 RRreeefferevttrooiooerriiggwiinnsaall-rreecFvviiioenewwamlwwpoPorFrlkkOssAehh\eetPeetFteO({Alldoo_cc2aa0ttee0dd7Raatte::v\Wi\DDeawat\taPa3Ff3bOM\eA\he~FHIiRRnaAAl\\CCNOoOvM M0V7M.IpOOdNNf)\GGuduieviddeaalnnoccpeeed-- iW Wnaat2t0ee0rr7i\TTfooo~xr `additional information reviews-completed\Final\PFOA\PFOA 2007Review\PFOA Final Nov07.pdf) developed in 2007 for additional information (CCAASS ## 333355--6677--11((ffrreeee aacciidd)) 5825-233633-551--66(66a--0m0m((oaaccniiidduffmlluusooarrliid,deeA))PFO) 3825-26-1 (ammonium salt, APFO) 335933 (slver sl) 22339955--0000-88 ((ppoottaassssiiuumm ssaalltt)) 333355.9-953--53((ssoidlvieurmssaallt)t) [Note: perfluorooctanoat3e3a5n-i9o5n-5do(essodnioutmhasavlet)a specific CAS number ] [Note: perfluorooctanoate anion does not have a specific CAS number.]

G Model CBI-6092; No. of Pages 9 ARTICLE IN PRESS Chemico-Biological Interactions xxx (2010) xxxxxx Contents lists available at ScienceDirect Chemico-Biological Interactions journal homepage: www.elsevier.com/locate/chembioint Hprt mutant frequency and p53 gene status in mice chronically exposed by inhalation to benzene Richard J.

That said, after thorough and critical review of the documentation by leading industry experts, our members' concerns (detailed in Attachment A) are not resolved.

3M GLP10-01-02; Interim Report 23 Analysis of PFBS, PFHS, and PFOS in Groundwater Samples Off-Site 610 Wells; September 2011 GLP10-01-02; Interim R eport 23 - A n a lysis o f PFBS.

Not Reported in F Supp 2d (Cite as- 2002 WL 1203836 (S.D N.Y.)) t> Only the Westlaw citation is currently available United States District Court, S D New York RUTGERSWERKE AG and FRENDO S p A , Plaintiffs, v ABEX CORPORATION, Pneumo Abex Corporation and Whitman Corporation, Defendants No. 93 CIV 2914 JFK.

tion, fabrication, and end use (largely con tile workers (studied by Dement and NIOSH) The former Soviet Union is the leading con struction) have been published, and asbestos and Quebec miners, millers, and factory temporary producer, followed by Quebec, is probably the best studied occupational and workers (studied by McDonald and others).

AR226-2812 TRADE SECRET Study Title Perfluorooctanoic Acid: Relationship Between Repeated Inhalation Exposures and Plasma PFOA Concentration in the Rat AUTHOR: Paul M.

Ann, otesp, ffyg., VO. 4$, Nk 4,pp. 309-326.2004 2004 British OeeMpaijonsl Hygime Society Published by Oxford University Press DO!

ARR EG -- 1828 Final Report on A Pharmacokinetic Study of Potassium Perfluorooctanoate in the Cynomolgus Monkey ~~T-757:!

A Pharmacokinetic Study of Potassium Perfluorooctanoate in the Cynomolgus Monkey Southern Research Institute Study ID: 9921.4 January 14, 2003 Final Report on A Pharmacokinetic Study of Potassium Perfluorooctanoate in the Cynomolgus Monkey To: 3M Corporation P.O.

UNITED ADVANCE ENGLISH COP Y NATIONS P.

Cancer Causes and Control (2005) 16:939953 DOI 10.1007/s10552-005-2301-3 Springer 2005 Occupational exposures and haematological malignancies: overview on human recent data Alexis Descatha1,*, Arash Jenabian2, Franc oise Conso3 & Jacques Ameille1 1Unite de pathologie professionnelle et de sante au travail, Ho^pital R.

Introduction Pediatric acute myeloid leukemia (AML) is a heterogeneous disease that accounts for 15-20% of the acute leukemias in children1 and is classified according to the WHO classification, which is based on non-random genetic aberrations.2 Over the decades the outcome of pediatric AML has improved and current overall survival rates range from 50% to 70%.3 The most important prognostic factors in pediatric AML are response to induction therapy and the cytogenetic and molecular subtype of the disease.4,5 Gilliland et al. postulated that the pathogenesis of AML requires both type I and type II mutations.6 Type II mutations are often chromosomal rearrangements of transcription factors leading to impaired differentiation of the hematopoietic cell, such as 11q23/MLL-rearranged, t(8;21)(q22;q22)[RUNX1-RUNXT1], inv(16)(p13q22)[CBFBMYH11], or t(15;17)(q21;q22) [PML-RARA].

AR226-2812 DuPont-12944 TRADE SECRET Study Title Perfluorooctanoic Acid: Relationship Between Repeated Inhalation Exposures and Plasma PFOA Concentration in the Rat Author: Paul M.

Graybar objects to each and every interrogatory to the extent that it seeks information 3 or documents not relevant to the subject matter of this action nor reasonably calculated to lead to 4 the discovery of admissible evidence as to this responding party. 5 4.